Three Questions about Costs and Cancer Clinical Trials

Bennett C.L. , Adams J.R. , Knox K.S. . Clinical trials: are they a good buy? J Clin Oncol. 2001; 19: 4330–4339.

Goldman D.P. . Costs of conducting cancer clinical trials. Manag Care Cancer. 2001; 3: 14–18.

Wagner J.L. , Alberts S.R. , Sloan J.A. . Incremental costs of enrolling cancer patients in clinical trials: a population-based study. J Natl Cancer Inst. Erratum: J Natl Cancer Inst. 2000; 92(2): 164-165. 1999; 91: 847–853.

Fireman B.H. , Fehrenbacher L. , Gruskin E.P. . Cost of care for patients in cancer clinical trials. J Natl Cancer Inst. 2000; 92: 136–142.

Bennett C.L. , Stinson T.J. , Vogel V. . Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol. 2000; 18: 2805–2810.

Chirikos T.N. , Ruckdeschel J.C. , Krischer J.P. . Impact of clinical trials on the costs of cancer care. Med Care. 2001; 39: 373–383.

Riley G.F. , Potosky A.L. , Lubitz J.D. . Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995; 33: 828–841.

Goldman D.P. , Schoenbaum M.L. , Potosky A.L. . Measuring the incremental cost of clinical cancer research. J Clin Oncol. 2001; 19: 105–110.

Evans W.K. , Dahrouge S. , Stapleton J. . An estimate of the cost of conducting phase II trials in lung cancer. Lung Cancer. 2000; 28: 85–95.

Gwede C.K. , Johnson D. , Trotti A. . Measuring the workload of clinical research coordinators, Part 1. Tools to study workload issues. Appl Clin Trials. 2000; 9: 40–44.

Gwede C.K. , Johnson D. , Trotti A. . Measuring the workload of clinical research coordinators, Part 2. Workload implications for sites. Appl Clin Trials 2000; 9: 42–47.

Gwede C.K. , Daniels S. , Johnson D. . Organization of clinical research services at investigative sites: implications for workload measurement. Drug Inf J. 2001; 35: 695–705.

Roche K. , Paul N. , Smuck B. . Factors affecting workload of cancer clinical trials: results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2002; 20: 545–556.

Moinpour C.M. . Costs of quality-of-life research in Southwest Oncology Group trials. J Natl Cancer Inst Monogr. 1996: 11–16.

Brown M. , McCabe M. , Schulman K.A. (eds). Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology economics workbook. J Natl Cancer Inst Monogr. 1998; 24.

Lyman G.H. . Economic analysis of randomized, controlled trials. Curr Oncol Rep. 2001; 3: 396–403.

Adams M.E. , McCall N.T. , Gray D.T. . Economic analysis in randomized controlled trials. Med Care. 1992; 30: 231–243.

Ramsey S.D. , McIntosh M. , Sullivan S.D. . Design issues for conducting cost-effectiveness analyses alongside clinical trials. Annu Rev Public Health. 2001; 22: 129–141.

Willan A.R. . Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data. Control Clin Trials. 2001; 22: 228–237.

Etzioni R. , Riley G.F. , Ramsey S.D. . Measuring costs: administrative claims data, clinical trials, and beyond. Med Care. 2002; 40(6 suppl): III63–III72.

Koopmanschap M.A. , Touw K.C. , Rutten F.F. . Analysis of costs and cost-effectiveness in multinational trials. Health Policy. 2001; 58: 175–186.

Coyle D. , Drummond M.F. . Analyzing differences in the costs of treatment across centers within economic evaluations. Int J Technol Assess Health Care. 2001; 17: 155–163.

Owen J.B. , Grigsby P.W. , Caldwell T.M. . Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04. Int J Radiat Oncol Biol Phys. 2001; 49: 633–639.

Bennett C.L. , Waters T.M. . Economic analyses in clinical trials for cooperative groups: operational considerations. Cancer Invest. 1997; 15: 448–453.

Bennett C.L. , Smith T.J. , George S.L. . Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol. 1995; 13: 2457–2463.

Djulbegovic B. , Lacevic M. , Cantor A. . The uncertainty principle and industry-sponsored research. Lancet. 2000; 356: 635–638.

Arnold K. , Vastag B. . Medicare to cover routine care costs in clinical trials. J Natl Cancer Inst. 2000; 92: 1032.

Brown M.L. . Cancer patient care in clinical trials sponsored by the National Cancer Institute: what does it cost? J Natl Cancer Inst. 1999; 91: 818–819.

Library of Congress. Thomas: Legislative Information on the Internet. Available at: http://thomas.loc.gov/ for a description of this legislation. Accessed December 19, 2002.

Lara P.N. Jr. , Higdon R. , Lim N. . Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001; 19: 1728–1733.

Taylor K.M. , Feldstein M.L. , Skeel R.T. . Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. J Clin Oncol. 1994; 12: 1796–1805.

George S.L. . Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol. 1996; 14: 1364–1370.

Chirikos T.N. . Cancer economics: on variations in the costs of treating cancer. Cancer Control. 2002; 9: 59–66.